Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
116 results about "Specific immunotherapy" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Allergen-specific immunotherapy is indicated in patients with allergic rhinitis/conjunctivitis and/or allergic asthma who have evidence of specific IgE antibodies to clinically relevant allergens (see Table 1). Skin prick testing (SPT) is the preferred method of testing for specific IgE antibodies.
Composition and methods for WTI specific immunotherapy
InactiveUS7063854B1Improve responseTumor rejection antigen precursorsPeptide/protein ingredientsAntigenDisease
Owner:CORIXA CORP +1
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor
ActiveUS20140356372A1Prevention and reduction of severityImprove efficacyPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsRegimenSeverity/Intensity
The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and / or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4Rα) antagonist such as an anti-IL-4Rα antibody.
Owner:REGENERON PHARM INC
Method for enhancing specific immunotherapies in cancer treatment
ActiveUS20140086932A1Enhance immune functionGood curative effectSnake antigen ingredientsPharmaceutical delivery mechanismCompound (substance)Targeted immunotherapy
Methods and compositions of the invention relate to the enhancement of specific immunotherapies in cancer treatment. In particular, aspects of the invention relate to novel approaches to boost immune function using a complex carbohydrate pharmaceutical compound alone or in combination with other targeted immunotherapy to increase the efficacy of immunotherapy of cancer.
Owner:PROVIDENCE HEALTH & SERVICES OREGON D B A EARLE A CHILES RES INST OF THE ROBERT W FRANZ CANCER RES CENT AT PROVIDENCE PORTLAND MEDICAL CENT +1
Compositions and methods for WT1 specific immunotherapy
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.
Owner:CORIXA CORP
Compositions and methods for WT1 specific immunotherapy
InactiveUS7115272B1Avoid developmentAvoid seizuresPeptide/protein ingredientsPeptide preparation methodsDiseaseImmunogenicity
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise a WT1 polypeptide comprising an immunogenic portion of WT1, wherein said WT1 polypeptide comprises the polypeptide of SEQ ID NO:144. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.
Owner:UNIV OF WASHINGTON +1
Compositions and Methods for Treating Cancer with DuoCARs
ActiveUS20190083596A1Prevent and ameliorate relapseAntibody mimetics/scaffoldsImmunoglobulins against cell receptors/antigens/surface-determinantsIntracellular signallingDisease
Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.
Owner:LENTIGEN TECH INC
Compositions and methods for WT1 specific immunotherapy
InactiveUS20060121046A1Variant to react with antigen-specific antisera and/or T-cell lines or clones is enhancedTumor rejection antigen precursorsPeptide/protein ingredientsAntigenPolynucleotide
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.
Owner:CORIXA CORP +1
ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
InactiveUS20130177574A1Market price thereof has been risingMinimizing IVIg related side effectAntipyreticAnalgesicsDiseaseAntigen
Provided herein are compositions comprising anti-HLA-Ib antibodies as IVIg mimetics and methods for using the same for the prevention, treatment, therapy and / or amelioration of inflammation induced diseases and allograft rejection. In certain embodiments, the anti-HLA-Ib antibodies (monoclonal antibodies or mixed monoclonal antibodies, recombinant or chimeric or humanized or human antibodies) strongly mimic IVIg in immunoreactivity to HLA class Ia (HLA-A, HLA-B and HLA-Cw) and Ib antigens (HLA-E, HLA-F and HLA-G). In certain embodiments, the anti-HLA-Ib antibodies (monoclonal or mixed monoclonal antibodies; recombinant, chimeric, humanized or human antibodies) strongly mimic IVIg in immunomodulatory or immunosuppressive activities. While anti-HLA-Ib mAbs can be used to restore anti-tumor activities of CD8+ T cells and Natural killer cells by passive therapy in cancer patients, methods are also provided herein to induce production of polyclonal anti-HLA-Ib antibodies in cancer patients for restoring anti-tumor activities of CD8+ T cells and NK cells, by active specific immunotherapy.
Owner:RAVINDRANATH MEPUR DR
Method for down-regulation of vegf
InactiveUS20070184023A1Improve survivalSignificant positive effectFungiBacteriaDiseaseVascular endothelial growth factor
The present invention provides for novel immunogenic variants of VEGF (vascular endothelial growth factor) which are useful in active specific immunotherapy against diseases that are characterized by overexpression of VEGF. The invention also relates to methods of treating such diseases (for instance cancer) as well as to various tools in molecular biology that assist in the provision of the immunogenic variants.
Owner:PHARMEXA
Allergen peptide fragments and use thereof
Owner:ANERGIS +1
Compositions and methods for WT1 specific immunotherapy
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.
Owner:CORIXA CORP
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor
ActiveUS10392439B2Improve efficacyImprove securityPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsRegimenAllergic reaction
The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and / or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4Rα) antagonist such as an anti-IL-4Rα antibody.
Owner:REGENERON PHARM INC
Compositions and method for WT1 specific immunotherapy
InactiveUS7329410B1Avoid developmentAvoid seizuresPeptide/protein ingredientsSnake antigen ingredientsImmunogenicitySpecific immunotherapy
A method for enhancing or inducing an immune response to WT1 is disclosed. In particular, the method comprises administering to a patient an immunogenic composition comprising an isolated polypeptide consisting of amino acids 1-249 of WT1 and a non-specific immune response enhancer.
Owner:UNIV OF WASHINGTON +1
Compositions and methods for wt1 specific immunotherapy
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.
Owner:CORIXA CORP +1
Dendritic Cell Therapeutic Agent and Immunotherapeutic Agent Comprising Peptide Derived from Telomerase, and Therapeutic Methods Using the Same
InactiveUS20170128557A1Good effectPeptide/protein ingredientsPharmaceutical delivery mechanismTelomeraseDisease
Provided is a dendritic cell therapeutic agent, and more particularly, a composition which include dendritic cells activated by peptides including a telomerase-derived peptide, the composition administered to treat an individual having disease and disorder symptoms which require target-specific treatments. Also, provided is a therapeutic method effective on diseases requiring target-specific immunotherapy. In the method, co-administration of the dendritic cell therapeutic agent and an immunotherapeutic agent including the telomerase-derived peptide results in decreased factors causing one of the disease and disorder symptoms requiring the target-specific treatment, such as cancer, in a tumor disease treatment.
Owner:KOREA STEM CELL BANK CO LTD +1
Compositions and methods for WT1 specific immunotherapy
InactiveUS7368119B2Improve responsePeptide/protein ingredientsPeptide preparation methodsAntigenDisease
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.
Owner:CORIXA CORP +1
Methods for Treating Allergy and Enhancing Allergen-Specific Immunotherapy by Administering an IL-4R Inhibitor
ActiveUS20180094069A1Improve efficacyImprove securityPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsRegimenAllergic reaction
The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and / or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4Rα) antagonist such as an anti-IL-4Rα antibody.
Owner:REGENERON PHARM INC
Compositions and methods for wt1 specific immunotherapy
InactiveUS20120301492A1Improve responseTumor rejection antigen precursorsPeptide/protein ingredientsAntigenDisease
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.
Owner:UNIV OF WASHINGTON CENT FOR COMMERICIALIZATION +1
Methods for Treating Allergy and Enhancing Allergen-Specific Immunotherapy by Administering an IL-4R Inhibitor
ActiveUS20180094070A1Improve efficacyImprove securityPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsRegimenAllergic reaction
The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and / or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4Rα) antagonist such as an anti-IL-4Rα antibody.
Owner:REGENERON PHARM INC
Contiguous Overlapping Peptides for Treatment of House Dust Mites Allergy
InactiveUS20150050301A1IgE bindingRelieve symptomsPeptide/protein ingredientsAntibody mimetics/scaffoldsCancer researchDust mites
Contiguous overlapping peptides (COPs) for the treatment of allergic patients by Specific Immunotherapy (SIT) are provided from the sequence of the major allergens of house dust mites Der p 1 and Der p 2. Such peptides while providing all potential T cell epitopes are devoid of the three dimensional structure of the original allergen, therefore reducing their ability to bind IgE. As a result increased amounts of COPs can be administered per injection, therefore reducing both the number of injections and the length of the immunotherapy treatment.
Owner:ANERGIS
Stable film agent medicinal composition containing allergen and preparation method thereof
ActiveCN102048712ABiologically active and stableEasy to useAllergen ingredientsImmunological disordersMedicineSpecific immunotherapy
The invention discloses a stable film agent medicinal composition containing an allergen, which comprises a theoretically effective amount of allergen, a film-forming material and a pharmaceutically acceptable carrier. In a preferable embodiment, the film-forming material accounts for 30 to 99 percent of the mass of the entire film agent medicinal composition. In addition, the invention also relates to a preparation method of the film agent medicinal composition. The application of the allergen film agent makes the standard medicament administration in allergen specific immunotherapy convenient.
Owner:ZHEJIANG WOLWO BIOTECH
Compositions and methods for WT1 specific immunotherapy
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.
Owner:CORIXA CORP
Method for enhancing specific immunotherapies in cancer treatment
ActiveUS9872909B2Good curative effectEnhance immune functionPharmaceutical delivery mechanismImmunoglobulins against cell receptors/antigens/surface-determinantsCancer therapyTargeted immunotherapy
Methods and compositions of the invention relate to the enhancement of specific immunotherapies in cancer treatment. In particular, aspects of the invention relate to novel approaches to boost immune function using a complex carbohydrate pharmaceutical compound alone or in combination with other targeted immunotherapy to increase the efficacy of immunotherapy of cancer.
Owner:PROVIDENCE HEALTH & SERVICES OREGON D B A EARLE A CHILES RES INST OF THE ROBERT W FRANZ CANCER RES CENT AT PROVIDENCE PORTLAND MEDICAL CENT +1
Compositions and methods for WT1 specific immunotherapy
InactiveUS7901693B2Avoid developmentAvoid seizuresBiocideTumor rejection antigen precursorsDiseaseAntigen
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.
Owner:CORIXA CORP
Compositions and methods for wt1 specific immunotherapy
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.
Owner:CORIXA CORP +1
Patient-specific immunotherapy for treating heterogeneous tumors
InactiveUS20160237163A1Extended reaction timeImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsDiseaseTreatment field
In the field of therapy, specifically patient-specific immune therapy for cancer, improved therapeutic modalities are provided for. The identity and dosage of the administered anti-tumor antibodies is determined and dynamically adjusted to the individual patient's condition, disease and / or treatment progression, thus providing anti-cancer treatment which may be particularly advantageous for the treatment of heterogeneous tumors.
Owner:SURI TECH
Compositions and methods for wt1 specific immunotherapy
Owner:CORIXA CORP
Contiguous overlapping peptides for treatment of house dust mites allergy
InactiveCN105307679ABacterial antigen ingredientsAntibody mimetics/scaffoldsSpecific immunityCancer research
Contiguous overlapping peptides (COPs) for the treatment of allergic patients by Specific Immunotherapy (SIT) are provided from the sequence of the major allergens of house dust mites Der p 1 and Der p 2. Such peptides while providing all potential T cell epitopes are devoid of the three dimensional structure of the original allergen, therefore reducing their ability to bind IgE. As a result increased amounts of COPs can be administered per injection, therefore reducing both the number of injections and the length of the immunotherapy treatment.
Owner:ANERGIS
Pharmaceutical composition for chemotherapy and immunotherapy combined treatment
PendingCN111375064AGood biocompatibilityGood sustained release effectOrganic active ingredientsPharmaceutical delivery mechanismLymphatic SpreadCombined treatment
The invention discloses a pharmaceutical composition for chemotherapy and immunotherapy combined treatment. The pharmaceutical composition is prepared from: a first component alginate and a second component chemotherapeutic drug; the alginate can form a porous gel with calcium ions in a body, and the alginate is one or more of sodium alginate, potassium alginate and ammonium alginate; and the second component chemotherapeutic drug can cause immungentic cell death. The pharmaceutical composition belongs to an efficient tumor-specific immunotherapy program, the tumor in situ can be effectively killed, and the growth of distant metastatic tumors and the recurrence probability of tumor can be suppressed and reduced through immune response.
Owner:SUZHOU INNOVATIVE BIOMATERIALS & PHARM CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com